← Neurocrine Biosciences, Inc. (NBIX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Neurocrine Biosciences, Inc. (NBIX)
Biological Products, (No Diagnostic Substances) · market cap $14.3B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-27 (est.)
Earnings
Pipeline
20
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Neurocrine Biosciences (NBIX) is a San Diego-based biopharma with an approved VMAT2 inhibitor, valbenazine (Ingrezza), generating $2.86B in 2025 revenue and growing rapidly, alongside a deep pipeline spanning CAH, epilepsy, schizophrenia, MDD, and MS. The company trades at ~$180.55 with a $18.15B market cap and holds $266.5M in net cash. The near-term setup centers on pipeline progression in CAH (Chronocort, Crinecerfont) and multiple Phase 3 readouts across neuropsychiatric indications.
The catalyst path
- 2026-10-27 (est.)Earningsimp 5/10
- 2027-07-15 (est.)Phase 3 · NBI-1065846imp 9/10
- 2027-07-15 (est.)Phase 3 · NBI-1065845imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Chronocort® | Phase 3 | Congenital Adrenal Hyperplasia |
| Valbenazine | Phase 3 | Tardive Dyskinesia |
| NBI-921352 | Phase 2 | SCN8A Developmental and Epileptic Encephalopathy Syndrome |
| Crinecerfont | Phase 3 | Congenital Adrenal Hyperplasia |
| NBI-74788 | Phase 2 | CAH - Congenital Adrenal Hyperplasia |
| NBI-1070770 | Phase 2 | Major Depressive Disorder |
| NBI-1065845 | Phase 3 | Major Depressive Disorder |
| TAK-041 | Phase 2 | Stable Schizophrenia |
| NBI-5788 | Phase 2 | Multiple Sclerosis |
| Luvadaxistat | Phase 2 | Schizophrenia |
| NBI-1065846 | Phase 2 | Anhedonia |
| TAK-831 | Phase 2 | Friedreich Ataxia |
| interleukin-4 PE38KDEL cytotoxin | Phase 2 | Brain and Central Nervous System Tumors |
| NBI-98854 | Phase 3 | Tardive Dyskinesia |
| NBI-1117568 | Phase 3 | Schizophrenia |
| NBI-827104 | Phase 2 | Epileptic Encephalopathy |
| Chronocort | Phase 3 | Congenital Adrenal Hyperplasia |
| Plenadren | Phase 2 | Primary Adrenal Insufficiency |
| Infacort® | Phase 3 | Adrenal Insufficiency |
| Cortef | Phase 2 | Congenital Adrenal Hyperplasia |
Price & technical context
3-month
-15.5%
6-month
+7.7%
12-month
+1.0%
52-wk range
$123.10–$185.50
vs 50-day MA
-9.6%
vs 200-day MA
-3.8%
Realized vol
34.7%
Max drawdown
-42.9%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NBIX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.